Sobi North America

Sobi is an international biopharmaceutical company dedicated to rare diseases, with a focus in immunology, hemophilia, inflammatory, genetic, and metabolic diseases. Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants aged <1 year. High-risk populations include infants and children who are born prematurely at 35 weeks’ gestational age or less, have bronchopulmonary dysplasia, or have certain forms of congenital heart disease. Administering RSV immunoprophylaxis can help prevent serious RSV disease in high-risk pediatric patients.
 View our 3D Booth